Special focus should be placed on the triple combination of anti-PD-1/L1, anti-CTLA-4, and anti-VEGF, as this combination has the broadest possible blockade out of all currently established HCC treatment options and thus potentially strongest synergism and anti-tumor effect. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.